A Phase 2 Study of Ifetroban in Systemic Sclerosis

Active, Not Recruiting Phase 2 NCT02682511

Study Description

Evaluating the Safety and Effectiveness of Ifetroban in Treating Diffuse Cutaneous Systemic Sclerosis and Pulmonary Arterial Hypertension

Registry ID:: NCT02682511
Conditions:: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Phase:: Phase 2
Target Enrollment:: 34 participants
Start Date:: January 1, 2017
Age Range:: 18–80 years
Healthy Volunteers:: No

KDH - Kokilaben Dhirubhai Ambani Hospital
Mumbai, MahārāshtraIndia, India
B. J. Government Medical College
Pune, MahārāshtraIndia, India
PGIMER
ChandigarhIndia, India
PGIMER
Chandigarh, ChandigarhIndia, India
Massachusetts General Hospital
Boston, MassachusettsUnited States, United States
Hospital for Special Surgery
New York, New YorkUnited States, United States
Cleveland Clinic - Florida
Weston, FloridaUnited States, United States
Thomas Jefferson University
Philadelphia, PennsylvaniaUnited States, United States
Johns Hopkins University
Baltimore, MarylandUnited States, United States
Medical University of South Carolina
Charleston, South CarolinaUnited States, United States
Baylor Research Institute
Dallas, TexasUnited States, United States
University of Nebraska Medical Center
Omaha, NebraskaUnited States, United States
The Universtity of Arizona Arthrtis Center
Tucson, ArizonaUnited States, United States
UCLA
Los Angeles, CaliforniaUnited States, United States

Check your eligibility and learn more about this study on TrialScreen.